Ritsuko Sasaki

TL;DR: Tests on triple‐negative breast cancers with a high density of tumor‐infiltrating lymphocytes found that MSI‐H tumors were absent in TIL‐high breast cancers, and examination of MMR proteins and PD‐L1 expression may merit further studies to yield predictive information for identifying patients who are likely to benefit from ICI.

TL;DR: Predictive markers for eribulin-based treatment responsiveness in patients with MBC are investigated by examining clinicopathological features, including several markers of immunocompetent cells in peripheral blood, which revealed that special histological types and high NLR might be factors related to low responsiveness to eribul-based regimens in patientsWith MBC.

TL;DR: The data are raised to raise the possibility of forkhead box A1 being a useful predictive marker for late recurrence and to provide new insights into the biology of FOXA1-high breast cancers.

TL;DR: In this paper , the authors investigated the relationship between TILs and the peripheral blood markers, platelet-to-lymphocyte ratios (PLRs) and neutrophil-tolymphocytes ratios (NLRs), in the same patients, using surgical specimens from 502 patients with invasive breast carcinoma without preoperative chemotherapy.

TL;DR: It is revealed that ER(+) and HER2 protein-overexpressing DCIS, especially ER-high tumors, frequently overexpress HER2protein without gene amplification, which may provide novel insights for understanding the biology of DCIS.